Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
On Thursday, JPMorgan reaffirmed its optimistic stance on Alnylam Pharmaceuticals (NASDAQ:ALNY), maintaining an Overweight rating and a price target of $330.00. According to InvestingPro data, the stock is currently trading near its 52-week high of $304.39, having delivered an impressive 94.35% return over the past year. Seven analysts have recently revised their earnings estimates upward for the upcoming period. The endorsement follows the release of IQVIA sales data for April, which analysts at JPMorgan have scrutinized for indications of Alnylam’s second-quarter performance and projections for the year 2025, particularly regarding their product Amvuttra.
The analysis by JPMorgan suggests that the recent IQVIA data could point to a robust start for Amvuttra, potentially leading to a significant outperformance in the second quarter and a positive adjustment to near-term estimates for the drug. The firm anticipates that the Transthyretin (TTR) franchise guidance will be raised in conjunction with the upcoming second-quarter results, scheduled for July 31, 2025. The company has demonstrated strong revenue growth of 17.21% over the last twelve months, with an impressive gross profit margin of 86.01%.
This outlook is in line with the positive feedback received from investor inquiries about weekly data, which seem to be increasingly factored into ongoing expectations. Despite the early stage of the data and the possibility of changes, the monthly figures from IQVIA are seen as confirming the strong initial momentum of Amvuttra’s launch.
The confidence expressed by JPMorgan also aligns with the results of a bullish cardiologist survey conducted in March and insights from a recent Key Opinion Leader (KOL) call. These sources have contributed to the firm’s continued endorsement of Alnylam Pharmaceuticals at an Overweight rating.
Alnylam Pharmaceuticals specializes in RNA interference (RNAi) therapeutics and has been gaining attention for its product Amvuttra, which is used in the treatment of polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. The company’s performance and the success of its TTR franchise are closely monitored by investors and analysts alike, with JPMorgan’s latest analysis providing a positive outlook for the near future. With a market capitalization of $38.07 billion and analyst targets ranging from $212 to $500, investors seeking deeper insights can access comprehensive analysis through InvestingPro, which offers exclusive financial health scores and additional ProTips for informed decision-making.
In other recent news, Alnylam Pharmaceuticals announced a 45% year-over-year increase in U.S. TTR revenues, reaching $359 million in the first quarter, with AMVUTTRA being a key driver. H.C. Wainwright reaffirmed its Buy rating with a $500 price target, citing the robust performance of AMVUTTRA for hereditary ATTR with polyneuropathy. Meanwhile, Stifel maintained its $345 target, optimistic about Amvuttra’s potential success in treating cardiomyopathy, supported by data from the HELIOS-B study. Additionally, JPMorgan adjusted its price target for Alnylam to $330, reflecting a positive outlook on the company’s financial health. Alnylam also reported shareholder approval of executive compensation plans and amendments to its certificate of incorporation. The company is set to present new data from its transthyretin amyloidosis programs at the Heart Failure 2025 Congress. Alnylam’s management remains focused on expanding its portfolio, with several clinical programs planned for 2025, including trials for nucresiran, zilebesiran, and elebsiran. These developments indicate continued progress in Alnylam’s strategic initiatives and product offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.